180 related articles for article (PubMed ID: 12812486)
1. XANES determination of the platinum oxidation state distribution in cancer cells treated with platinum(IV) anticancer agents.
Hall MD; Foran GJ; Zhang M; Beale PJ; Hambley TW
J Am Chem Soc; 2003 Jun; 125(25):7524-5. PubMed ID: 12812486
[TBL] [Abstract][Full Text] [Related]
2. Quantitative measurement of the reduction of platinum(IV) complexes using X-ray absorption near-edge spectroscopy (XANES).
Hall MD; Daly HL; Zhang JZ; Zhang M; Alderden RA; Pursche D; Foran GJ; Hambley TW
Metallomics; 2012 Jun; 4(6):568-75. PubMed ID: 22569908
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
4. Platinum (IV)-coordinate polymers as intracellular reduction-responsive backbone-type conjugates for cancer drug delivery.
Yang J; Liu W; Sui M; Tang J; Shen Y
Biomaterials; 2011 Dec; 32(34):9136-43. PubMed ID: 21889206
[TBL] [Abstract][Full Text] [Related]
5. The cellular distribution and oxidation state of platinum(II) and platinum(IV) antitumour complexes in cancer cells.
Hall MD; Dillon CT; Zhang M; Beale P; Cai Z; Lai B; Stampfl AP; Hambley TW
J Biol Inorg Chem; 2003 Sep; 8(7):726-32. PubMed ID: 12884089
[TBL] [Abstract][Full Text] [Related]
6. The preparation and characterization of trans-platinum(IV) complexes with unusually high cytotoxicity.
Cubo L; Hambley TW; Sanz Miguel PJ; Carnero A; Navarro-Ranninger C; Quiroga AG
Dalton Trans; 2011 Jan; 40(2):344-7. PubMed ID: 20936210
[TBL] [Abstract][Full Text] [Related]
7. Investigations using fluorescent ligands to monitor platinum(IV) reduction and platinum(II) reactions in cancer cells.
New EJ; Duan R; Zhang JZ; Hambley TW
Dalton Trans; 2009 Apr; (16):3092-101. PubMed ID: 19352538
[TBL] [Abstract][Full Text] [Related]
8. Model platinum nucleobase and nucleoside complexes and antitumor activity: X-ray crystal structure of [PtIV(trans-1R,2R-diaminocyclohexane)trans-(acetate)2(9-ethylguanine)Cl]NO3.H2O.
Ali MS; Khan SR; Ojima H; Guzman IY; Whitmire KH; Siddik ZH; Khokhar AR
J Inorg Biochem; 2005 Mar; 99(3):795-804. PubMed ID: 15708801
[TBL] [Abstract][Full Text] [Related]
9. The direct mapping of the uptake of platinum anticancer agents in individual human ovarian adenocarcinoma cells using a hard X-ray microprobe.
Ilinski P; Lai B; Cai Z; Yun W; Legnini D; Talarico T; Cholewa M; Webster LK; Deacon GB; Rainone S; Phillips DR; Stampfl AP
Cancer Res; 2003 Apr; 63(8):1776-9. PubMed ID: 12702562
[TBL] [Abstract][Full Text] [Related]
10. Application of fluorescence microscopy for investigation of cellular distribution of dinuclear platinum anticancer drugs.
Kalayda GV; Zhang G; Abraham T; Tanke HJ; Reedijk J
J Med Chem; 2005 Aug; 48(16):5191-202. PubMed ID: 16078838
[TBL] [Abstract][Full Text] [Related]
11. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
Xu Z; Wang Z; Yiu SM; Zhu G
Dalton Trans; 2015 Dec; 44(46):19918-26. PubMed ID: 26514681
[TBL] [Abstract][Full Text] [Related]
12. Hydrolysis triggers oxidation of a trans diamine platinum(II) anticancer complex.
Pizarro AM; Munk VP; Navarro-Ranninger C; Sadler PJ
Angew Chem Int Ed Engl; 2003 Nov; 42(43):5339-42. PubMed ID: 14613170
[No Abstract] [Full Text] [Related]
13. Importance of platinum(II)-assisted platinum(IV) substitution for the oxidation of guanosine derivatives by platinum(IV) complexes.
Choi S; Vastag L; Larrabee YC; Personick ML; Schaberg KB; Fowler BJ; Sandwick RK; Rawji G
Inorg Chem; 2008 Feb; 47(4):1352-60. PubMed ID: 18220340
[TBL] [Abstract][Full Text] [Related]
14. Platinum(II) complexes with l-methionylglycine and l-methionyl-l-leucine ligands: synthesis, characterization and in vitro antitumoral activity.
Kaluderović GN; Schmidt H; Paschke R; Kalinowski B; Dietrich A; Mueller T; Steinborn D
J Inorg Biochem; 2007 Mar; 101(3):543-9. PubMed ID: 17223197
[TBL] [Abstract][Full Text] [Related]
15. An unexpected biotransformation pathway for tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in the L1210 cell line.
Chaney SG; Gibbons GR; Wyrick SD; Podhasky P
Cancer Res; 1991 Feb; 51(3):969-73. PubMed ID: 1988140
[TBL] [Abstract][Full Text] [Related]
16. Oxidation of 3,6-dioxa-1,8-octanedithiol by platinum(IV) anticancer prodrug and model complex: kinetic and mechanistic studies.
Huo S; Shen S; Liu D; Shi T
J Phys Chem B; 2012 Jun; 116(22):6522-8. PubMed ID: 22574871
[TBL] [Abstract][Full Text] [Related]
17. Reduction of cis,trans,cis-[PtCl2(OCOCH3)2(NH3)2] by aqueous extracts of cancer cells.
Nemirovski A; Kasherman Y; Tzaraf Y; Gibson D
J Med Chem; 2007 Nov; 50(23):5554-6. PubMed ID: 17949066
[TBL] [Abstract][Full Text] [Related]
18. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
Horváth V; Blanárová O; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Fedorocko P; Kozubík A
Gynecol Oncol; 2006 Jul; 102(1):32-40. PubMed ID: 16364413
[TBL] [Abstract][Full Text] [Related]
19. XANES investigation of the Co oxidation state in solution and in cancer cells treated with Co(III) complexes.
Bonnitcha PD; Hall MD; Underwood CK; Foran GJ; Zhang M; Beale PJ; Hambley TW
J Inorg Biochem; 2006 May; 100(5-6):963-71. PubMed ID: 16624414
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and characterization of platinum(II) oxadiazoline complexes and their in vitro antitumor activity in platinum-sensitive and -resistant cancer cell lines.
Coley HM; Sarju J; Wagner G
J Med Chem; 2008 Jan; 51(1):135-41. PubMed ID: 18072719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
